Emerging Cancer Vaccine Markets.pdf
《Emerging Cancer Vaccine Markets.pdf》由会员分享,可在线阅读,更多相关《Emerging Cancer Vaccine Markets.pdf(267页珍藏版)》请在三一文库上搜索。
1、Emerging Cancer Vaccine Markets Rures adquireret umbraculi, etiam tremulus matrimonii libere senesceret appSeptember 2010 Kalorama Information A division of MarketR 38 East 29th Street Sixth Floor New York, New York 10016 212.807 .2660 t 800.298.5603 t 212.807 .2676 f Copyright 2010 Kalorama Inform
2、ation Reproduction without written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited Copyright 2010 Kalorama Information Reproduction without written permission, in any media now in existence or hereafter developed, in whole or in any p
3、art, is strictly prohibited CANCER VACCINE MARKET MARKET FORECASTS, NEW DEVELOPMENTS AND PIPELINE ANALYSIS The Cancer Vaccine Market: Market Forecasts, New Developments and Pipeline Analysis has been prepared by Kalorama Information. We serve business and industrial clients in the United States and
4、abroad with a complete line of information services and research publications. Kalorama Information Market Intelligence Reports are specifically designed to aid the action-oriented executive by providing a thorough presentation of essential data and concise analysis. Author: Melissa Elder Publicatio
5、n Date: September 2010 38 East 29th Street New York, New York 10016 (800) 298-5699 Outside the U.S. (212) 807-2657 FAX: (212) 807-2676 www.KaloramaI E-MAIL: COPYRIGHT 2010 Kalorama Information a division of MarketR, Inc. iCopyright 2010 Kalorama Information Reproduction without written permission,
6、in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY1 Introduction.1 Disease Burden 2 Scope and Methodology4 Size and Growth of the Market6 Issues and Trends Affecting Market10 Leading Competitors.11 CH
7、APTER TWO: INTRODUCTION.13 Introduction.13 Cancer Descriptions 14 Timeline of Cancer Vaccine Developments.16 History and Growth of the Cancer Treatment Market .17 Types of Vaccines 20 Antigen/Adjuvant Vaccines.21 Whole Cell Tumor Vaccines22 Dendritic Cell (DC) Vaccines.22 Viral Vectors and DNA Vacci
8、nes23 Idiotype Vaccines23 Types of Therapeutic Vaccines.23 Patient-Specific Vaccines .24 Prostate Specific Antigen24 Sialyl Tn24 Heat Shock Proteins25 Ganglioside Molecules .25 Carcinoembryonic Antigen (CEA)25 MART-1.25 Tyrosinase.26 Adjuvants 26 Industry Structure.27 Demographics and Statistics.28
9、Growing and Aging Population.34 Tobacco Use and Obesity Increases Cancer Risk.39 Tobacco Use39 Obesity41 Life Expectancy and Cancer .45 ii New Developments in the Cancer Vaccine Market Copyright 2010 Kalorama Information Reproduction without written permission, in any media now in existence or herea
10、fter developed, in whole or in any part, is strictly prohibited CHAPTER THREE: CERVICAL CANCER VACCINES.51 Overview51 Description of Vaccines on the Market.55 Gardasil/Silgard.55 Cervarix56 Description of Vaccines in Development.56 V503 .56 RG3484.56 PV701.57 Lovaxin C .57 VGX-3100.57 CA-9 .57 Marke
11、t Summary59 Current and Potential Competitors and Analysis, 201562 CHAPTER FOUR: COLON/RECTAL CANCER VACCINES.65 Overview65 Description of Vaccines on the Market.69 OncoVAX69 Description of Vaccines in Development.69 OncoVAX69 TroVAX.70 CEA VRP Vaccine (AVX701).70 IMA910.71 CDX-1307.71 Tumor Associa
12、ted Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine 71 MKC1106-PP.71 GI-4000 72 GVAX72 Oncophage .72 CRS-207 .73 Lapuleucel-T.73 Market Summary76 Potential Competitors and Analysis, 201577 CHAPTER FIVE: LUNG CANCER VACCINES79 Overview79 Description of Vaccines in Development.84 Lucanix.84 MAGE-A3
13、 Peptide84 Stimuvax.84 Table of Contents iii Copyright 2010 Kalorama Information Reproduction without written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited EGF Cancer Vaccine85 HyperAcute Lung85 GI-4000.86 Oncophage86 TG 401086 Lung
14、VAX.87 Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine.87 DCVax-Lung.87 Market Summary91 Potential Competitors and Analysis, 2015.92 CHAPTER SIXL LYMPHOMA VACCINES93 Overview.93 Description of Vaccines in Development.98 BiovaxID.98 MyVax.98 Market Summary100 Potential Competitors
15、 and Analysis, 2015.101 CHAPTER SEVEN: MELANOMA VACCINES.103 Overview.103 Description of Vaccines on the Market107 Description of Vaccines in Development.108 MVAX108 Allovectin-7.108 MDX-1379 with Combination Treatment MDX-010 109 Oncophage110 MAGE-A3 ASCI110 ALVAC Vaccine 111 HyperAcute Melanoma.11
16、1 Market Summary114 Potential Competitors and Analysis, 2015.118 CHAPTER EIGHT: PROSTATE CANCER VACCINES123 Overview.123 Description of Vaccines on the Market127 Provenge.127 Description of Vaccines in Development.128 DCVax-Prostate128 GVAX128 Copyright 2010 Kalorama Information Reproduction without
17、 prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. CHAPTER ONE Executive Summary INTRODUCTION In April 2010, the cancer vaccine market experienced one of the largest achievements for therapeutic vaccine treatment of cance
18、rthe approval of prostate cancer vaccine Provenge. Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVaxs Canvaxin, Aphtons Insegia, Progenics GMK vaccine, and Biomiras Theratope. Desp
19、ite setbacks many developers are hopeful of a turnaround. With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity a
20、nd an influx of market opportunities. The approval of Provenge will likely reinstall investor confidence in cancer vaccines, which has been damaged by poor commercial results in previous therapeutic vaccine approvals and disappointing Phase III studies in other once promising developments. Chapter O
21、ne: Executive Summary 2 Copyright 2010 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. DISEASE BURDEN Worldwide cancer affects between 11 and 12 million people each year. This n
22、umber is expected to increase to 15 million each year by 2020. Worldwide approximately 24 million people are living with cancer and nearly 8 million people die. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patie
23、nts in underdeveloped countries. Some of the most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder Lung cancer is the most common cancer worldwide accounting for approximately 14% of all cancer incidences. Lung cancer
24、is most prevalent in the developed world accounting for more than half of cases reported. Men are most affected accounting for nearly 70 percent of cases reported each year, compared to 30 percent women. Asia has the highest incidence of lung cancer worldwide, followed by Europe and North America. T
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Emerging Cancer Vaccine Markets
链接地址:https://www.31doc.com/p-3753986.html